From: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Study procedures | Screening Treatment cohort | Treatment phase | EOT | Survival FU | |||||
---|---|---|---|---|---|---|---|---|---|
(D 1–21) | D1g | W8g | W16g | W26g | W39h | QW13h | Q26W for 2 years after end of treatment | ||
Check inclusion criteria and exclusion criteria for treatment phase + Drug specific selection criteria | X | ||||||||
Informed consenta | X | ||||||||
Medical history | X | ||||||||
Drug dispensingb | X | X | X | X | X | X | |||
Physical examination | X | X | X | X | X | X | X | ||
Vital signs and ECOG PS | X | X | X | X | X | X | X | X | |
ECG | X | ||||||||
AE/SAE assessment | X | X | X | X | X | X | X | ||
Concomitant medication | X | X | X | X | X | X | X | ||
QoL (V) | X | X | X | X | X | X | |||
Laboratory Assessmentsc | X | X | X | X | X | X | X | ||
Pregnancy testd, e | X | Monthly as long as use of contraception is required, see drug specific amendment | |||||||
Central lab sampling | X | ||||||||
Plasma/serum samples | X | X | X | X | X | X | X | ||
Urinei | X | X | X | ||||||
Fecesi | X | X | |||||||
Tumor biopsy | X | X | X | ||||||
Other materialf | X | X | X | X | |||||
Tumor assessment | X | X | X | X | X | X | X | ||
Survival follow-up | X |